SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

NovoSeven

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already on the market since 1999 (original) and 2014 (RT formulation).
Why 3/10
NovoSeven is an already-approved, marketed drug with no pending PDUFA date, pivotal readout, or Advisory Committee meeting scheduled in the next ~12 months. The only active clinical program is a small Phase 4 post-marketing safety study in India for postpartum hemorrhage, which is not a registrational catalyst. NovoSeven is a minor product within Novo Nordisk's rare disease segment (roughly 6% of total company revenue), which itself is dwarfed by the GLP-1 franchise. With no binary catalyst on the horizon, the impact score is capped at 3.
Actionable Insight NEUTRAL

NovoSeven has no near-term binary catalyst. The Phase 4 postpartum hemorrhage safety study in India (NCT07157423) is still recruiting with no announced readout date. For Novo Nordisk investors, the drug is a mature, low-growth asset within a tiny segment of the business. The key drivers for NVO remain the GLP-1 franchise (Ozempic, Wegovy) and pipeline assets like oral semaglutide and CagriSema, not NovoSeven.

Price Chart

Loading chart...

Executive Summary

NovoSeven (eptacog alfa) is an FDA-approved recombinant clotting factor marketed by Novo Nordisk since 1999 for treating bleeding episodes in hemophilia patients with inhibitors and other rare bleeding disorders. It is a mature, commercialized product facing growing competition from SevenFact (eptacog beta) and potential future biosimilars. For a Novo Nordisk investor, NovoSeven is a very small piece of the story: the company's rare disease segment contributed roughly 6% of 2025 revenue, and NovoSeven is just one product within that segment. The GLP-1 diabetes/obesity franchise (Ozempic, Wegovy) dominates the investment thesis. There are no near-term binary catalysts for this drug.

How It Works

NovoSeven is a lab-made version of a natural blood-clotting protein called Factor VIIa. When injected, it helps blood clot by bypassing the missing or blocked clotting factors (VIII and IX) that cause bleeding in hemophilia patients. It works only at the site of an injury, triggering a cascade that forms a clot and stops bleeding.

Trial Status

NovoSeven was first FDA-approved in 1999. The room-temperature-stable formulation (NovoSeven RT) was approved in 2014. It is a marketed product with approved indications for hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann's thrombasthenia, and acquired hemophilia. A Phase 4 post-marketing safety study (NCT07157423) is recruiting in India to evaluate safety in severe postpartum hemorrhage, with 64 patients targeted across 14 sites, last updated September 2026.

The Two-Sided Case

▲ Bull Case3
NovoSeven is a well-established, FDA-approved therapy with multiple labeled indications (hemophilia A/B with inhibitors, congenital FVII deficiency, Glanzmann's thrombasthenia, acquired hemophilia), giving it a broad addressable patient population.
The rare disease portfolio grew 9% at constant exchange rates in 2025, per Novo Nordisk's annual report, showing steady demand for products like NovoSeven.
A Phase 4 study exploring safety in severe postpartum hemorrhage in India could support future label expansion or guideline inclusion, opening a new use case.
▼ Bear Case4
NovoSeven faces direct competition from SevenFact (eptacog beta, LFB), a newer recombinant Factor VIIa approved for hemophilia A/B with inhibitors in patients aged 12 and older, which has been winning formulary conversions at some institutions.
Patent protection is eroding; biosimilar versions such as AryoSeven (AryoGen, Iran) already exist outside the US, and the broader biosimilar patent cliff could eventually bring US competition.
NovoSeven is a negligible financial contributor to Novo Nordisk. The company's 2025 revenue was DKK 309 billion (~$49B), with the rare disease segment accounting for only about 6% of sales. The stock's performance is overwhelmingly driven by GLP-1 products (Ozempic, Wegovy), not NovoSeven.
No upcoming binary catalysts mean the drug will not drive any share-price movement for NVO in the foreseeable future.

Upcoming Catalysts

  • Phase 4 postpartum hemorrhage safety study (NCT07157423) in India, still recruiting, no topline readout date announced
  • Potential biosimilar competition as patents expire

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 9

Hover a chip for the title
1 fda.gov2 drugs.com3 novomedlink.com4 annualreport.novonordisk.com5 marketscreener.com6 drugpatentwatch.com7 nhpri.org8 hemophilianewstoday.com9 ema.europa.eu